Skip to main content

Nogapendekin Alfa Inbakicept Dosage

Medically reviewed by Drugs.com. Last updated on Jun 18, 2024.

Applies to the following strengths: pmln 400 mcg/0.4 mL

Usual Adult Dose for Bladder Cancer

Induction dose: 400 mcg administered intravesically with Bacillus Calmette-Guérin (BCG) once a week for 6 weeks


Maintenance dose: After induction, 400 mcg intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19 (for a total of 15 doses)

Maximum dose: For patients with complete response at month 25 and later, maintenance instillations with BCG may be administered once a week for 3 weeks at months 25, 31, and 37 for a maximum of 9 additional instillations.

Duration of therapy: Until disease persistence after second induction, disease recurrence or progression, unacceptable toxicity, or a maximum of 37 months.

Comments:

Use: In combination with BCG for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Report suspected adverse reactions to www.fda.gov/medwatch

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

Patient advice:

More about nogapendekin alfa inbakicept

Patient resources

Other brands

Anktiva

Professional resources

Other brands

Anktiva

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.